Impact of Screening on Staging and Survival of Hepatocellular Carcinoma (HCC) in HIV / HBV-Coinfected Patients

Marianne Harris¹, Lynn E. Taylor², Maria Hernandez³, Harout Tossonian⁴, Hartwig Klinker⁵, Erica Kaufman⁶, Ziba Jalali⁷, Maaz Badshah⁸, Brian Conway⁴, Rena Fox⁹, Morris Sherman¹⁰, Norbert Bräu¹¹, Liver Cancer in HIV Study Group

¹St. Paul's Hospital & University of British Columbia, Vancouver, BC, CANADA, ²Miriam Hospital & Brown University of Miami, Miami, FL, USA, ⁴Vancouver Infectious Diseases Centre, Vancouver, BC, CANADA, ⁵Universitätsklinikum Würzburg, Würzburg, GERMANY, ⁶Southern Illinois Healthcare, Carbondale, IL, USA, ⁷University of California Los Angeles, CA, USA, ⁸Indiana University, Indianapolis, IN, USA, ⁹University of California San Francisco, San Francisco, CA, USA, ¹⁰Toronto General Hospital & University of Toronto, Toronto, ON, CANADA, ¹¹James J. Peters VA Medical Center, Bronx, NY & Icahn School of Medicine at Mount Sinai, Divisions of Infectious Diseases & Liver Diseases, New York, NY, USA

Background

Methods

• Current recommendations for HCC screening in patients chronically infected with the hepatitis B virus (HBV) are based on a randomized controlled trial from China. (Zhang BH, J Cancer Res Clin Oncol 2004)

 No data are available on the effectiveness of HCC screening in HIV/HBVcoinfected patients.

HCC Staging

	Screened N=30	Not Screened N=24	Р	Scree N=	ned Not Screened N=24	Р
BCLC Stage, n (%) A B C } Advanced, D } Incurable Stages C+D	13 (43%) 8 (27%) 7 (23%) 2 (7%) 9 (30%)	1 (4%) 3 (13%) 14 (58%) 6 (25%) 20 (83%)	0.001	Potentially Curative Therapy Radiofrequency Ablation Ethanol Injections Surgical Resection Liver Transplantation17 (5) 32 32 32 32 33Effective, Non-Curative Therapy Transarterial Chemoembolization / (TACE) Sorafenib Sorafenib + TACE6 (20) 50 50 50 10	7%) 1 (4%) 0 0 1 0 %) 5 (21%) 1 2 2 2	<0.001
CLIP Score, Mean	1.48	2.96	0.001	Ineffective or no Therapy 7 (2	%) 18 (75%)	

HCC Therapy

- Retrospective analysis of consecutive HCC cases in HIV/HBV-coinfected patients 1992 – 2011 with data on initial presentation, identified through local tumour registries.
- Subjects recruited from 29 centres in 8 countries:
 - Canada (3), United States (35), Brazil (4), United Kingdom (3),
 - Germany (2), Spain (6), Australia (1)


N=54, all male

Patients were divided into two groups:

- Screened
 - n = 30 (56%)
- asymptomatic, diagnosis was made through screening procedure,
 - i.e. abnormal screening AFP or imaging studies
- Not Screened
- n = 24 (44%)
- symptomatic, diagnosis was made through work-up of symptoms, not screening results
- Analysis of tumour characteristics, staging, therapy, and survival
- Estimation of lead time of screened pts. using tumor doubling time method:
- Lead Time (T) = Tumour Doubling Time * 3log (median tumour size not screened/ screened) * 1/log(2) (Schwartz M, *Cancer*, 1961)

BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program

Survival adjusted for lead time of 9.4 months in screened patients



Here: T = 80 days * 3log (8.7 cm/3.8 cm) * 1/log(2) = 287 days (9.4 months)

Published median HCC tumor doubling time in HIV-negative patients: 80 days
(Cucchetti A, *J Hepatol,* 1992; Okada S, *Hepatogastroenterol1993*)

Patient Characteristics

	Screened N=30	Not Screened N=24	Р
Age (yrs), Mean	48.3	50.1	0.38
Male Sex	30 (100%)	24 (100%)	1.0
Alcohol abuse	8 (30%)	5 (23%)	0.59
Child-Turcotte-Pugh Score, Mean	5.90	7.54	0.002
On HIV Therapy	25 (89%)	18 (78%)	0.28
HIV Parameters CD4+ Cells (per mm3), Median HIV RNA <400 Copies/mL	310 22 (76%)	338 15 (63%)	0.96 0.29

HCC Tumour Characteristics

	Screened N=30	Not Screened N=24	P	
Hepatic Lesions				
Solitary Tumours	18 (60%)	6 (25%)	0.01	
Multiple /Infiltrative Tumours	12 (40%)	18 (75%)		

	Median Survival	1-Year	2-Year Estim. Survival
Screen	90 months	59%	59%
No Screen	2.6 months	18%	6%

Multi-Variable Cox Regression Analysis

Risk Factor	Univariate Hazard Ratio for Death	Univariate P	Multi-Variable Hazard Ratio for Death	95% Confidence Interval	Multi- variable P
HIV RNA (per log10 copies/mL)	1.39	0.012	1.21	1.21-2.27	0.002
HCC Screening	0.16	<0.001	0.26	0.09-0.74	<0.001
Age at diagnosis (per year)	1.09	0.001	1.08	1.02-1.14	0.006
CTP Score (per unit)	1.28	0.002			
Effective HCC Therapy	0.20	<0.001			
AFP (per 1000 ng/mL)	1.002	0.049			
BCLC stages A&B vs. C&D	0.46	0.038			
AST / ALT ratio (per unit)	1.51	0.037			

CTP, Child-Turcotte-Pugh; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer



Median Size Largest Tumour (cm), for Tumor Doubling Time	3.8	8.7	0.002
Eligibility for Liver Transplantation (Milan Criteria)	12 (43%)	1 (5%)	0.005
Portal Vein Thrombosis Extrahepatic Metastases	5 (17%) 2 (7%)	9 (38%) 4 (17%)	0.083 0.245
Alpha-fetoprotein Level Median (ng/mL),	223	1236	0.071

•Many HIV/HBV-coinfected patients with HCC were not diagnosed through screening

 An HCC diagnosis through screening was associated with earlier HCC stages, more HCC therapy, and independently predicted better survival





To contribute your cases of HCC in HIV patients for further studies, please contact:

Norbert Bräu norbert.brau@va.gov

www.HCCinHIV.org

CAHR, St. John's, NL, 1 – 4 May 2014, Abstract No. P054